CING (Cingulate) OCF Margin %: 0.00% (As of Mar. 2026)


CING Cingulate Inc CING
35 GF Score
Price $4.83
! 1 Warning Sign
View Full Analysis

What is Cingulate OCF Margin %?

Cingulate CING -1.03% 35 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CING with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Cingulate ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Cingulate's Cash Flow from Operations for the three months ended in Mar. 2026 was $-6.91 Mil. Cingulate's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Cingulate's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Cingulate's current OCF Yield % is -30.17%.

The historical rank and industry rank for Cingulate's OCF Margin % or its related term are showing as below:


CING's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Cingulate OCF Margin % Related Terms

Cingulate OCF Margin % Historical Data

* Premium members only.

The historical data trend for Cingulate's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate OCF Margin % Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CING
35GF Score
Cingulate Inc CING
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Cingulate's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.245/0
= %

Cingulate's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.913/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Cingulate (CING) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cingulate and its competitors. According to the industry distribution chart, Cingulate ranks #999999 out of 959 companies in the Biotechnology industry.
Is Cingulate's OCF Margin % too high?
Cingulate's current OCF Margin % is 0.00%. Based on the distribution chart, Cingulate ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cingulate has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's OCF Margin % compare to TIL and XLO?
According to the Biotechnology industry distribution chart, Cingulate ranks #999999 out of 959 companies for OCF Margin %. This places Cingulate in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cingulate and its competitors. Cingulate's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Cingulate's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cingulate (CING), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
35GF Score

Get the complete analysis for CING

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.83
Price